Actively Recruiting

All Genders
NCT06092450

Deep Learning Radiomics Model for Predicting Post-cystectomy Outcome in Muscle Invasive Bladder Cancer

Led by First Affiliated Hospital of Chongqing Medical University · Updated on 2025-05-31

500

Participants Needed

1

Research Sites

95 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Muscle invasive bladder cancer (MIBC) has a poor prognosis even after radical cystectomy. Postoperative survival stratification based on radiomics and deep learning may be useful for treatment decisions to improve prognosis. This study was aimed to develop and validate a deep learning radiomics model based on preoperative enhanced CT to predict postoperative survival in MIBC.

CONDITIONS

Official Title

Deep Learning Radiomics Model for Predicting Post-cystectomy Outcome in Muscle Invasive Bladder Cancer

Who Can Participate

All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients with pathologically confirmed muscle invasive bladder cancer after radical cystectomy
  • Contrast-enhanced CT scan performed less than two weeks before surgery
  • Complete CT image data and clinical data available
Not Eligible

You will not qualify if you...

  • Patients who received neoadjuvant therapy before surgery
  • Non-urothelial carcinoma diagnosis
  • Poor quality of CT images
  • Incomplete clinical and follow-up data

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Department of Urology, The First Affiliated Hospital of Chongqing Medical University

Chongqing, Chongqing Municipality, China, 400016

Actively Recruiting

Loading map...

Research Team

Z

Zongjie Wei

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here